|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 10.3 USD | -0.53% |
|
-5.96% | -8.39% |
| Apr. 05 | Arbutus Biopharma Obtains Favorable Court Order in Moderna Patent Lawsuit | MT |
| Apr. 04 | Moderna Suffers Setback in Lawsuit by Arbutus | MT |
Roivant Sciences Ltd. reported earnings results for the first quarter ended June 30, 2022. For the first quarter, the company reported sales was USD 4.32 million compared to USD 7.74 million a year ago. Net loss was USD 331.81 million compared to USD 82.18 million a year ago.
Basic loss per share from continuing operations was USD 0.48 compared to USD 0.13 a year ago.
| 1st Jan change | Capi. | |
|---|---|---|
| -8.39% | 8.35B | |
| +25.02% | 672B | |
| +24.08% | 550B | |
| -6.33% | 351B | |
| +14.99% | 317B | |
| +7.31% | 292B | |
| +3.26% | 211B | |
| +0.78% | 203B | |
| -10.59% | 144B | |
| -7.33% | 141B |
ROIVANT SCIENCES LTD. 
